Elite Pharmaceuticals, Inc.

Equities

ELTP

US28659T2006

Pharmaceuticals

Market Closed - OTC Markets 03:58:25 2024-04-22 pm EDT 5-day change 1st Jan Change
0.1272 USD -2.15% Intraday chart for Elite Pharmaceuticals, Inc. -5.78% -9.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Elite Pharmaceuticals, Inc., Q3 2024 Earnings Call, Feb 15, 2024
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System Stimulant CI
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR to Marketing Partner Prasco, LLC CI
Transcript : Elite Pharmaceuticals, Inc., Q2 2024 Earnings Call, Nov 15, 2023
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic Product CI
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer CI
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study CI
Transcript : Elite Pharmaceuticals, Inc., Q1 2024 Earnings Call, Aug 15, 2023
Elite Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Transcript : Elite Pharmaceuticals, Inc., 2023 Earnings Call, Jun 30, 2023
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Elite Pharmaceuticals, Inc Appoints Mark Pellegrino as its Chief Financial Officer CI
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product CI
Elite Pharmaceuticals, Inc. Announces Resignation of Robert Chen as Treasurer and Secretary CI
Elite Pharmaceuticals, Inc. Announces Resignation of Robert Chen as Chief Financial Officer CI
Transcript : Elite Pharmaceuticals, Inc., Q3 2023 Earnings Call, Feb 15, 2023
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Elite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence Study CI
Transcript : Elite Pharmaceuticals, Inc., Q2 2023 Earnings Call, Nov 15, 2022
Elite Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Elite Pharmaceuticals Inc. and Lannett Company, Inc. Jointly Terminated the License, Supply and Distribution Agreement for Vigabatrin CI
Elite Pharmaceuticals, Inc. Appoints Kirko Kirkov as Chief Commercial Officer CI
Elite Pharmaceuticals Inc. Receives Notification from Lannett Company, Inc. for Terminating the License, Supply and Distribution Agreement CI
Chart Elite Pharmaceuticals, Inc.
More charts
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Company’s products include Phentermine HCl 37.5mg tablets, Phendimetrazine Tartrate 35mg tablets, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.
More about the company
  1. Stock Market
  2. Equities
  3. ELTP Stock
  4. News Elite Pharmaceuticals, Inc.
  5. Elite Pharmaceuticals' Chief Financial Officer Marc Bregman Resigns